- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
Showing 1–12 of 84 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
|---|---|---|---|---|---|---|---|---|---|---|
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
2021.07 |
145,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
4 mg |
-80°C |
2026.04 |
202,00Â € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Rixathon® |
10 mg/mL |
– |
2 mg |
-80 °C |
2026.03 |
245,00Â € |
||
CD3 , DLL3 |
Bi-specific T-cell engager |
Imdelltra® |
2,38 mg/mL |
– |
0,25 mg |
-80°C |
2027.06 |
1.511,45Â € |
||
CD3 , TCR targeting domain |
Bispecific fusion protein |
Kimmtrak® |
0,2 mg/mL |
– |
0.01 mg |
tba |
tba |
4.602,00Â € |
||
B cell maturation antigen , CD3 |
Bispecific Antibody |
Tecvayli® |
10 mg/mL |
– |
1 mg |
-80°C |
2024.10 |
410,00Â € |
||
Tissue factor (TF) |
Antibody-drug conjugate (ADC) |
Tivdak® |
10 mg/mL |
– |
1 mg |
tba |
tba |
1.665,00Â € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Herzuma® |
21 mg/mL |
– |
6 mg |
tba |
tba |
356,00Â € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Ontruzant® |
21 mg/mL |
– |
2 mg |
tba |
tba |
159,00Â € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Kanjinti® |
21 mg/mL |
– |
6 mg |
-80°C |
2025.01 |
367,00Â € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Zercepac® |
21 mg/mL |
– |
6 mg |
-80°C |
2026.08 |
367,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2028.11 |
169,00Â € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Ogivri® |
21 mg/mL |
– |
6 mg |
-80°C |
2025.10 |
451,00Â € |
||
HER2 |
Antibody-drug conjugate (ADC) |
Enhertu® |
20 mg/mL |
– |
2 mg |
-80 °C |
2027.05 |
476,00Â € |
||
HER2 |
Antibody-drug conjugate (ADC) |
Kadcyla® |
20 mg/mL |
– |
2 mg |
-80 °C |
2027.10 |
386,00Â € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Trazimera® |
21 mg/mL |
– |
2 mg |
-80 °C |
2026.09 |
164,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2020.08 |
169,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2021.02 |
169,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2021.08 |
169,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2026.12 |
169,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin Hylecta® |
120 mg/mL Trastuzumab + 2000 IU/mL Hyaluronidase |
– |
30 mg Trastuzumab + 750 IU Hyaluronidase |
-80 °C |
2026.01 |
1.582,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2019.11 |
169,00Â € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2020.12 |
169,00Â € |